Results 21 to 30 of about 218,137 (295)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]

Critical Care, 2018
Debasree Banerjee, Sean Monaghan, Runping Zhao, Thomas Walsh, Amy Palmisciano, Gary S. Phillips, Steven Opal, Mitchell M. Levy   +7 more
doaj   +3 more sources

Programmed death-ligand 1 expression in surgically resected thymomas. [PDF]

Updates Surg
Abstract Thymomas are one of the most common neoplasms of the anterior mediastinum with limited therapeutic options, particularly in advanced stages. The molecular profiles of these tumors remain poorly investigated. This study aims to evaluate the expression of programmed death ligand 1 (PD-L1) in a selected cohort of intentionally curative ...
Frasca L, Sarubbi A, Longo F, Marziali V, Patirelis A, Crucitti P, Ambrogi V.   +6 more
europepmc   +5 more sources

Programmed Cell Death Ligand 1 Expression in Osteosarcoma [PDF]

Cancer Immunology Research, 2014
Abstract Programmed cell death ligand 1 (PDL1, also known as B7H1) is a cell-surface protein that suppresses the cytotoxic CD8+ T-cell–mediated immune response. PDL1 expression and its clinical relevance in sarcomas are not well understood.
Jacson K, Shen, Gregory M, Cote, Edwin, Choy, Pei, Yang, David, Harmon, Joseph, Schwab, G Petur, Nielsen, Ivan, Chebib, Soldano, Ferrone, Xinhui, Wang, Yangyang, Wang, Henry, Mankin, Francis J, Hornicek, Zhenfeng, Duan   +13 more
openaire   +2 more sources

Clinicopathological features of thymoma with the expression of programmed death-ligand 1 [PDF]

Annals of Oncology, 2018
Programmed death ligand 1 (PD-L1) is reportedly expressed in various malignancies and is considered a prognostic factor. We attempted to reveal the usefulness of the PD-L1 expression as a prognostic factor in patients with thymoma.Eighty-one patients with thymoma who underwent surgical resection between 2004 and 2015 were retrospectively reviewed.
Shuhei, Hakiri, Takayuki, Fukui, Shunsuke, Mori, Koji, Kawaguchi, Shota, Nakamura, Naoki, Ozeki, Taketo, Kato, Masaki, Goto, Yasushi, Yatabe, Kohei, Yokoi   +9 more
openaire   +2 more sources

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition

Diagnostics, 2021
Periampullary cancers (PACs) are characterized by tumor-infiltrating lymphocytes (TILs), severe fibrosis, and epithelial to mesenchymal transition (EMT).
Nishant Thakur, Kwang Yeol Paik, Gyoyeon Hwang, Yosep Chong   +3 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer [PDF]

Korean Journal of Clinical Oncology, 2017
Purpose Programmed death-1 and its ligands (PD-L1 and PD-L2) can induce T-cell apoptosis in many solid tumors, although there is limited information regarding their roles in colorectal cancer.
Jee Hyun Ahn, Hyun Yong Lee, Dong Hyun Kang, Geum Jong Song, Tae Sung Ahn, Myoung Won Son, Moon Soo Lee, Moo-Jun Baek   +7 more
doaj   +1 more source

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner

Frontiers in Immunology, 2017
Functional impairment of T-cells and a concomitant augmented expression of programmed death-1 (PD-1) have been observed in visceral leishmaniasis patients, as well as in experimental models for visceral and cutaneous leishmaniasis.
Christodoulos Filippis, Katharina Arens, Gaetan Aime Noubissi Nzeteu, Gabriele Reichmann, Zoe Waibler, Peter Crauwels, Ger van Zandbergen, Ger van Zandbergen   +7 more
doaj   +1 more source

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites

Molecules, 2020
Evidence suggests that programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) targeted inhibitors act as an immune checkpoint blockade, indicating that these compounds may be useful in cancer immunotherapy by inhibiting the immune response ...
Nam-Hui Yim, Young Soo Kim, Hwan-Suck Chung   +2 more
doaj   +1 more source

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources